Why the study?
Does Mean Platelet Component Concentration (MPC) correlate with P-selectin (CD62P) expression for assessing platelet activation in ACS patients undergoing PTCA?
Does Mean Platelet Component Concentration (MPC) correlate with P-selectin (CD62P) expression for assessing platelet activation in ACS patients undergoing PTCA?
The MPC parameter on an automated hematology system correlates well with flow cytometry for monitoring platelet activation and response to antiplatelet therapy in ACS patients.
Answers are grounded in this paper and cite their sources.
May support simpler MPC monitoring of platelet activation in ACS; leaves open whether it improves outcomes versus flow cytometry in PTCA.
The study investigated the clinical usefulness of a new method to evaluate platelet activation and the variability of platelet response to anti-platelet therapy in patients undergoing percutaneous transluminal coronary angioplasty (PTCA). Platelet activation was assessed in parallel by a new method for platelet density measurements (MPC, Mean Platelet Component Concentration), on the automated ADVIA 120 Hematology System and by the classic measurement of P-selectin (CD62P) expression, on a fluorescence flow cytometer. Patients received a loading dose of clopidogrel (300 mg; n = 29) or a bolus of abciximab (0.25 mg/kg; n = 15). Blood samples were collected before (baseline) and at different times after PTCA and antiplatelet drugs administration. Our data showed a close inverse correlation between the change in MPC and the CD62P fluorescence surface marker expression (r = -0.776, P<0.0001). Individual platelet activation determinations in patients receiving either clopidogrel or abciximab showed a variation in platelet activation as assayed by MPC and CD62P expression. Patients were characterized as having either high platelet activity upon admission and positive response to treatment or no detectable platelet activation before or after treatment. This study demonstrates the heterogeneity of platelet activation states in ACS patients undergoing coronary angioplasty. The present work also illustrates the potential use of the MPC parameter, generated on an automated hematology system, to define high risk patients and to monitor the variability of platelet response to anti-platelet therapies.
No takes yet. Share an insight, caveat, or question.
Boughrassa et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: